New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies

Di Yan, Andrew Blauvelt, Amit K. Dey, Rachel S. Golpanian, Samuel T. Hwang, Nehal N. Mehta, Bridget Myers, Zhen rui Shi, Gil Yosipovitch, Stacie Bell, Wilson Liao

Research output: Contribution to journalReview articlepeer-review

Abstract

Although psoriasis and psoriatic arthritis (PsA) have been classically considered to be diseases of the skin and joints, respectively, emerging evidence suggests that a combination of innate and environmental factors creates widespread immune dysfunction, affecting multiple organ systems. A greater understanding of the pathogenesis of psoriasis and the systemic effects of psoriatic inflammation has allowed for the development of new, more effective treatments. The second portion of this two-part review series examines the comorbidities associated with psoriasis and PsA as well as the most recent advances in targeted systemic therapies for these conditions.

Original languageEnglish (US)
JournalJournal of Investigative Dermatology
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Fingerprint

Dive into the research topics of 'New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies'. Together they form a unique fingerprint.

Cite this